Cargando…

Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015

OBJECTIVES: The aim of this paper was to describe the time trends in the prevalence of multimorbidity and polypharmacy in Flanders (Belgium) between 2000 and 2015, while controlling for age and sex. METHODS: Data were available from Intego, a Flemish-Belgian general practice-based morbidity registra...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Akker, Marjan, Vaes, Bert, Goderis, Geert, Van Pottelbergh, Gijs, De Burghgraeve, Tine, Henrard, Séverine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372187/
https://www.ncbi.nlm.nih.gov/pubmed/30753214
http://dx.doi.org/10.1371/journal.pone.0212046
_version_ 1783394697684713472
author van den Akker, Marjan
Vaes, Bert
Goderis, Geert
Van Pottelbergh, Gijs
De Burghgraeve, Tine
Henrard, Séverine
author_facet van den Akker, Marjan
Vaes, Bert
Goderis, Geert
Van Pottelbergh, Gijs
De Burghgraeve, Tine
Henrard, Séverine
author_sort van den Akker, Marjan
collection PubMed
description OBJECTIVES: The aim of this paper was to describe the time trends in the prevalence of multimorbidity and polypharmacy in Flanders (Belgium) between 2000 and 2015, while controlling for age and sex. METHODS: Data were available from Intego, a Flemish-Belgian general practice-based morbidity registration network. The practice population between 2000 and 2015 was used as the denominator, representing a mean of 159,946 people per year. Age and gender-standardised prevalence rates were used for the trends of multimorbidity and polypharmacy in the total population and for subgroups. Joinpoint regression analyses were used to analyse the time trends and breaks in trends, for the entire population as well as for specific age and sex groups. RESULTS: Overall, in 2015, 22.7% of the population had multimorbidity, while the overall prevalence of polypharmacy was 20%. Throughout the study period the standardised prevalence rate of multimorbidity rose for both sexes and in all age groups. The largest relative increase in multimorbidity was observed in the younger age groups (up to the age of 50 years). The prevalence of polypharmacy showed a significant increase between 2000 and 2015 for all age groups except the youngest (0–25 years). CONCLUSION: For all adult age groups multimorbidity and polypharmacy are frequent, dynamic over time and increasing. This asks for both epidemiological and interventional studies to improve the management of the resulting complex care.
format Online
Article
Text
id pubmed-6372187
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63721872019-03-01 Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015 van den Akker, Marjan Vaes, Bert Goderis, Geert Van Pottelbergh, Gijs De Burghgraeve, Tine Henrard, Séverine PLoS One Research Article OBJECTIVES: The aim of this paper was to describe the time trends in the prevalence of multimorbidity and polypharmacy in Flanders (Belgium) between 2000 and 2015, while controlling for age and sex. METHODS: Data were available from Intego, a Flemish-Belgian general practice-based morbidity registration network. The practice population between 2000 and 2015 was used as the denominator, representing a mean of 159,946 people per year. Age and gender-standardised prevalence rates were used for the trends of multimorbidity and polypharmacy in the total population and for subgroups. Joinpoint regression analyses were used to analyse the time trends and breaks in trends, for the entire population as well as for specific age and sex groups. RESULTS: Overall, in 2015, 22.7% of the population had multimorbidity, while the overall prevalence of polypharmacy was 20%. Throughout the study period the standardised prevalence rate of multimorbidity rose for both sexes and in all age groups. The largest relative increase in multimorbidity was observed in the younger age groups (up to the age of 50 years). The prevalence of polypharmacy showed a significant increase between 2000 and 2015 for all age groups except the youngest (0–25 years). CONCLUSION: For all adult age groups multimorbidity and polypharmacy are frequent, dynamic over time and increasing. This asks for both epidemiological and interventional studies to improve the management of the resulting complex care. Public Library of Science 2019-02-12 /pmc/articles/PMC6372187/ /pubmed/30753214 http://dx.doi.org/10.1371/journal.pone.0212046 Text en © 2019 van den Akker et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
van den Akker, Marjan
Vaes, Bert
Goderis, Geert
Van Pottelbergh, Gijs
De Burghgraeve, Tine
Henrard, Séverine
Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015
title Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015
title_full Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015
title_fullStr Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015
title_full_unstemmed Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015
title_short Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015
title_sort trends in multimorbidity and polypharmacy in the flemish-belgian population between 2000 and 2015
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372187/
https://www.ncbi.nlm.nih.gov/pubmed/30753214
http://dx.doi.org/10.1371/journal.pone.0212046
work_keys_str_mv AT vandenakkermarjan trendsinmultimorbidityandpolypharmacyintheflemishbelgianpopulationbetween2000and2015
AT vaesbert trendsinmultimorbidityandpolypharmacyintheflemishbelgianpopulationbetween2000and2015
AT goderisgeert trendsinmultimorbidityandpolypharmacyintheflemishbelgianpopulationbetween2000and2015
AT vanpottelberghgijs trendsinmultimorbidityandpolypharmacyintheflemishbelgianpopulationbetween2000and2015
AT deburghgraevetine trendsinmultimorbidityandpolypharmacyintheflemishbelgianpopulationbetween2000and2015
AT henrardseverine trendsinmultimorbidityandpolypharmacyintheflemishbelgianpopulationbetween2000and2015